A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein... | NCT01445626 | Trialant
CompletedObservationalUpdated Feb 18, 2013
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
ClinicalTrials.gov ID
NCT01445626
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
87Actual
Last Update Posted
Feb 18, 2013Estimated
Start Date
Oct 2011
Primary Completion Date
Jan 2012Actual
Completion Date
Jan 2012Actual
Brief Summary
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
Macular Edema
dexamethasone intravitreal implant 0.7 mg
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Macular oedema in the study eye due to BRVO or CRVO
Received at least 2 OZURDEX® injections in the study eye
Exclusion Criteria:
Received OZURDEX® injections as part of or during any clinical study